 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV today announced the completion of the clinical study report CSR of a Phase 2 clinical trial of the Companys M-001 universal influenza vaccine candidate. The trial in 120 adult volunteers was supported by the U.S. National Institute of Allergy and Infectious Diseases NIAID, part of the National Institutes of Health NIH. 